A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response-Reference-Cited by-同舟云学术

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Published:2012-03 Issue:7391 Volume:483 Page:613-617
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Chen Zhao,Cheng Katherine,Walton Zandra,Wang Yuchuan,Ebi Hiromichi,Shimamura Takeshi,Liu Yan,Tupper Tanya,Ouyang Jing,Li Jie,Gao Peng,Woo Michele S.,Xu Chunxiao,Yanagita Masahiko,Altabef Abigail,Wang Shumei,Lee Charles,Nakada Yuji,Peña Christopher G.,Sun Yanping,Franchetti Yoko,Yao Catherine,Saur Amy,Cameron Michael D.,Nishino Mizuki,Hayes D. Neil,Wilkerson Matthew D.,Roberts Patrick J.,Lee Carrie B.,Bardeesy Nabeel,Butaney Mohit,Chirieac Lucian R.,Costa Daniel B.,Jackman David,Sharpless Norman E.,Castrillon Diego H.,Demetri George D.,Jänne Pasi A.,Pandolfi Pier Paolo,Cantley Lewis C.,Kung Andrew L.,Engelman Jeffrey A.,Wong Kwok-Kin

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature10937.pdf

Reference30 articles.

1. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–480 (2002)

2. Huang, M. E. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567–572 (1988)

3. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010)

4. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009)

5. Ahrendt, S. A. et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J. Natl. Cancer Inst. 95, 961–970 (2003)

Cited by 414 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models;Nature Communications;2024-05-31

2. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in KRAS - and BRAF -mutant cancer cells;Science Signaling;2024-05-14

3. Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy;Cancers;2024-02-26

4. Applying deep learning to segmentation of murine lung tumors in pre-clinical micro-computed tomography;Translational Oncology;2024-02

5. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy;Journal of Experimental & Clinical Cancer Research;2024-01-02